Mansfield CA, Metcalfe KA, Snyder C, Lindeman GJ, Posner J, Friedman S, Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer, Lynch HT, Narod SA, Evans DG, Liede A. Preferences for breast cancer prevention among women with a BRCA1 or BRCA2 mutation. Hered Cancer Clin Pract. 2020 Sep 29;18(20). doi: 10.1186/s13053-020-00152-z
Rees K, Takeda A, Martin N, Ellis L, Wijesekara D, Vepa A, Das A, Hartley L, Stranges S. Mediterranean-Style diet for the primary and secondary prevention of cardiovascular disease: a Cochrane Review. Glob Heart. 2020 Aug 12;15(1):56. doi: 10.5334/gh.853
Uthman OA, Hartley L, Rees K, Taylor F, Ebrahim S, Clarke A. Multiple risk factor interventions for primary prevention of CVD in LMIC: a Cochrane review. Glob Heart. 2017 Sep;12(3):199-208.e. doi: 10.1016/j.gheart.2016.03.639
Yosipovitch G, Reaney M, Eckert L, Nelson L, Clark M, Abbe A, Ardeleanu M, Radin A, Gadkari A. Validation of the peak pruritus numerical rating scale: results from clinical studies of dupilumab in adults with moderate-to-severe atopic dermatitis. Poster presented at the Australasian College of Dermatologists 50th Annual Scientific Meeting; May 2017. Sydney, Australia. [abstract] Australas J Dermatol. 2017 May; 58(S1):106-7. Previously presented at the 2017 American Academy of Dermatology Annual Meeting. doi: 10.1111/ajd.21_12652
Spelman LJ, Lebwohl M, Mordin M, Mallya UG, Gnanasakthy A, Fox T. Secukinumab treatment provides fast relief from patient-reported psoriasis burden. Poster presented at the 48th Australasian College of Dermatologists Annual Scientific Meeting; May 2015. Adelaide, Australia. [abstract] Australas J Dermatol. 2015 May; 56(Suppl 2):73.
Foley P, Sherif B, Mallya UG, Fox T, Gottlieb AB. Secukinumab treatment sustains patient-reported outcome benefits through 1 year. Poster presented at the 48th Australasian College of Dermatologists Annual Scientific Meeting; May 2015. Adelaide, Australia. [abstract] Australas J Dermatol. 2015 May; 56(Suppl 2):56.
Sinclair R, McLeod L, Mallya UG, Fox T, Strober B. Psoriasis patients with PASI90 response achieve greater health-related quality of life improvements than those with PASI75 response. Poster presented at the 48th Australasian College of Dermatologists Annual Scientific Meeting; May 2015. Adelaide, Australia. [abstract] Australas J Dermatol. 2015 May; 56(S2):68.